Findings could potentially lead to new drug therapy for Cushing disease

FINDINGS:

Cushing disease is a life-threatening disorder most commonly triggered by tumors, often benign, in the pituitary glands, resulting in excess production of adrenocorticotrophic hormone (ACTH). The condition is marked by progressive weight gain, excessive fatty tissue deposits and a rounding of facial features, known as "moon face," and can lead to diabetes, hypertension, osteoporosis, obesity and psychological disturbances.

Cushing disease, which is more common in women than men, is also associated with a three- to four-fold increase in the risk of premature death. But what drives the tumor growth and the excess production of ACTH?

UCLA researchers and their colleagues have now found that testicular orphan nuclear receptor 4 (TR4) is overexpressed in the tumors. The scientists discovered that by knocking down TR4 in lab mice, they were able to reverse tumor growth and excess ACTH production.

IMPACT:

The findings could potentially lead to a drug therapy for Cushing disease.

AUTHORS:

Study authors included Li Du, Marvin Bergsneider, Leili Mirsadraei, Steven H. Young, William H. Yong and Anthony P. Heaney of UCLA; Johan W. Jonker of the University of Groningen in the Netherlands; and Michael Downes and Ronald M. Evans of Gene Expression Laboratory at the Salk Insitute of Biological Studies in La Jolla, Calif.

JOURNAL:

The findings were published in the May 21 issue of the journal Proceedings of the National Academy of Sciences.

Source: University of California - Los Angeles Health Sciences

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment